Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in IPF (Russian Practice)
NCT03208933Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Started Oct 2017; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03208933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208933.